best practices capping reimbursement glp-1 drugs wellness stipend Ultimate Guide to Stipends for Employee-First Companies Big news for the obesity

However, despite previous reports on the potential advantage posed by GLP1-based multi-agonists in the management of obesity and metabolic disease, as recently exemplified by the dramatic body weight-lowering actions of the GLP1/GIP dual agonist, tirzepatide 47 , to our knowledge, no study has addressed to date the pharmacological characterization of GLP1-based unimolecular multi-agonists for management of reproductive and metabolic alterations of PCOS, using suitable preclinical models, as pre-requisite for their application in clinics

doi: 10.1097/NUR.0000000000000423

The demographics tell an important story too

Victoza package insert

Hansen DV, Hanson JE, Sheng M

The rates of invasive recurrence and metastatic disease were high in both groups, but the researchers found that people using GLP-1s had a 74% lower risk of invasive or metastatic cancer progression